WO2011082268A2 - Substituted naphthalenyl-pyrimidine compounds - Google Patents

Substituted naphthalenyl-pyrimidine compounds Download PDF

Info

Publication number
WO2011082268A2
WO2011082268A2 PCT/US2010/062437 US2010062437W WO2011082268A2 WO 2011082268 A2 WO2011082268 A2 WO 2011082268A2 US 2010062437 W US2010062437 W US 2010062437W WO 2011082268 A2 WO2011082268 A2 WO 2011082268A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
alkyl
heteroatoms selected
butyl
Prior art date
Application number
PCT/US2010/062437
Other languages
English (en)
French (fr)
Other versions
WO2011082268A3 (en
Inventor
Mark A. Ashwell
Chris Brassard
Audra Dalton
Jason Hill
Robert Nicewonger
David Vensel
Original Assignee
Arqule Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc. filed Critical Arqule Inc.
Priority to CA2788450A priority Critical patent/CA2788450A1/en
Priority to EP10841700.7A priority patent/EP2519519A4/en
Priority to NZ601508A priority patent/NZ601508A/xx
Priority to CN2010800649939A priority patent/CN102822169A/zh
Priority to AU2010339531A priority patent/AU2010339531A1/en
Priority to KR1020127020146A priority patent/KR20130005263A/ko
Publication of WO2011082268A2 publication Critical patent/WO2011082268A2/en
Publication of WO2011082268A3 publication Critical patent/WO2011082268A3/en
Priority to ZA2012/05726A priority patent/ZA201205726B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2010/062437 2009-12-30 2010-12-29 Substituted naphthalenyl-pyrimidine compounds WO2011082268A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2788450A CA2788450A1 (en) 2009-12-30 2010-12-29 Substituted naphthalenyl-pyrimidine compounds
EP10841700.7A EP2519519A4 (en) 2009-12-30 2010-12-29 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS
NZ601508A NZ601508A (en) 2009-12-30 2010-12-29 Substituted naphthalenyl-pyrimidine compounds and the use thereof in the treatment of cancer
CN2010800649939A CN102822169A (zh) 2009-12-30 2010-12-29 取代的萘基-嘧啶化合物
AU2010339531A AU2010339531A1 (en) 2009-12-30 2010-12-29 Substituted naphthalenyl-pyrimidine compounds
KR1020127020146A KR20130005263A (ko) 2009-12-30 2010-12-29 치환된 나프탈레닐-피리미딘 화합물
ZA2012/05726A ZA201205726B (en) 2009-12-30 2012-07-30 Substituted naphthalenyl-pyrimidine compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29091309P 2009-12-30 2009-12-30
US61/290,913 2009-12-30

Publications (2)

Publication Number Publication Date
WO2011082268A2 true WO2011082268A2 (en) 2011-07-07
WO2011082268A3 WO2011082268A3 (en) 2011-10-20

Family

ID=44225054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/062437 WO2011082268A2 (en) 2009-12-30 2010-12-29 Substituted naphthalenyl-pyrimidine compounds

Country Status (10)

Country Link
US (1) US8173808B2 (US08173808-20120508-C00223.png)
EP (1) EP2519519A4 (US08173808-20120508-C00223.png)
KR (1) KR20130005263A (US08173808-20120508-C00223.png)
CN (1) CN102822169A (US08173808-20120508-C00223.png)
AU (1) AU2010339531A1 (US08173808-20120508-C00223.png)
CA (1) CA2788450A1 (US08173808-20120508-C00223.png)
NZ (1) NZ601508A (US08173808-20120508-C00223.png)
TW (1) TW201139410A (US08173808-20120508-C00223.png)
WO (1) WO2011082268A2 (US08173808-20120508-C00223.png)
ZA (1) ZA201205726B (US08173808-20120508-C00223.png)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2485589A1 (en) * 2009-09-04 2012-08-15 Biogen Idec MA Inc. Heteroaryl btk inhibitors
CN104193644A (zh) * 2014-09-27 2014-12-10 张远强 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途
US9290511B2 (en) 2011-11-15 2016-03-22 Xention Limited Thieno-pyrimidines, useful as potassium channel inhibitors
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103289A2 (en) * 2010-02-17 2011-08-25 Jasco Pharmaceuticals, LLC Imidazole-2, 4-dione inhibitors of casein kinase 1
WO2014086453A1 (en) * 2012-12-07 2014-06-12 Merck Patent Gmbh Azaheterobicyclic compounds
AU2016341109A1 (en) * 2015-10-18 2018-06-07 Onco Therapies Llc Compositions and methods of regulating cancer related disorders and diseases
WO2022147622A1 (en) * 2021-01-07 2022-07-14 Ontario Institute For Cancer Research (Oicr) Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE834993C (de) 1944-05-27 1952-03-27 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 2, 6-Dioxy-4-aminopyrimidin-5-aminosulfonsaeure in Form ihrer Salze
GB681712A (en) 1949-09-14 1952-10-29 Burroughs Wellcome Co Improvements in or relating to therapeutically useful pyrimidine compounds
US2691655A (en) 1952-05-24 1954-10-12 Burroughs Wellcome Co 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
DE4025891A1 (de) 1990-08-16 1992-02-20 Bayer Ag Pyrimidyl-substituierte acrylsaeureester
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
KR20040066296A (ko) 2003-01-17 2004-07-27 주식회사 엘지생명과학 3-(2-아미노-4-피리미디닐)-2-나프톨 구조를 갖는사이클린 의존 키나아제 저해제
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
AU2004257289A1 (en) 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
KR20070084067A (ko) 2004-10-13 2007-08-24 와이어쓰 Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체
CA2637245A1 (en) 2006-01-17 2007-07-26 Signal Pharmaceuticals, Llc Inhibitors of tnf.alpha., pde4 and b-raf, compositions thereof and methods of use therewith
DE102006008880A1 (de) 2006-02-27 2007-09-06 Merck Patent Gmbh Aminopyrimidinderivate
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
EP1903037A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
EP1903038A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren
US7985745B2 (en) * 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
JP2010507698A (ja) 2006-10-25 2010-03-11 チバ ホールディング インコーポレーテッド 熱安定性のカプセル化顔料
EA200970669A1 (ru) 2007-02-06 2010-02-26 Пфайзер Инк. Производные 2-амино-5,7-дигидро-6н-пирроло[3,4-d]пиримидина в качестве ингибиторов hsp-90, предназначенные для лечения рака
US20100297009A1 (en) 2007-03-13 2010-11-25 Technion Research & Development Foundation Ltd. Self-assembled polyhedral multimeric chemical structures
CA2681516A1 (en) 2007-03-22 2008-09-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of janus kinases
WO2008121570A1 (en) 2007-03-29 2008-10-09 Irm Llc Compounds and methods for modulating g protein-coupled receptors
CN101679418A (zh) * 2007-04-06 2010-03-24 诺瓦提斯公司 用作蛋白质激酶抑制剂的[2,6]萘啶类化合物
DE102007017656A1 (de) 2007-04-12 2008-10-16 Henkel Ag & Co. Kgaa Biheteroaryl-Metallkomplexe als Bleichkatalysatoren
US20080287452A1 (en) 2007-05-16 2008-11-20 Wyeth Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
RU2478099C2 (ru) 2007-07-27 2013-03-27 Актелион Фармасьютиклз Лтд Производные 2-аза-бицикло[3.3.0]октана
TW200904799A (en) 2007-07-27 2009-02-01 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
US20090048282A1 (en) * 2007-08-14 2009-02-19 Wyeth Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2519519A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2485589A1 (en) * 2009-09-04 2012-08-15 Biogen Idec MA Inc. Heteroaryl btk inhibitors
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
US9290511B2 (en) 2011-11-15 2016-03-22 Xention Limited Thieno-pyrimidines, useful as potassium channel inhibitors
CN104193644A (zh) * 2014-09-27 2014-12-10 张远强 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10245263B2 (en) 2015-12-23 2019-04-02 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10933065B2 (en) 2015-12-23 2021-03-02 Arqule Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11020400B2 (en) 2015-12-23 2021-06-01 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof

Also Published As

Publication number Publication date
CN102822169A (zh) 2012-12-12
WO2011082268A3 (en) 2011-10-20
US8173808B2 (en) 2012-05-08
CA2788450A1 (en) 2011-07-07
US20110166137A1 (en) 2011-07-07
AU2010339531A1 (en) 2012-08-23
NZ601508A (en) 2013-07-26
KR20130005263A (ko) 2013-01-15
TW201139410A (en) 2011-11-16
ZA201205726B (en) 2013-09-25
EP2519519A2 (en) 2012-11-07
EP2519519A4 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
US8563567B2 (en) Substituted heterocyclic compounds
CA2837727C (en) Substituted imidazopyridinyl-aminopyridine compounds
US8580803B2 (en) Substituted pyrrolo-aminopyrimidine compounds
US8497276B2 (en) Substituted indolo-piperidine compounds
US8815854B2 (en) Substituted imidazopyridinyl compounds
US8173808B2 (en) Substituted naphthalenyl-pyrimidine compounds
US8541407B2 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
EP2379556A1 (en) Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
EP3189036A1 (en) Compositions and methods for treating proliferation disorders
WO2010114896A1 (en) Substituted indolo-pyridinone compounds
CA2756807A1 (en) Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
US8343977B2 (en) Substituted triazolo-pyrimidine compounds
EP2414361A1 (en) Substituted heterocyclic compounds
CA2756809A1 (en) Substituted tetrahydropyrazolo-pyrido-azepin compounds
AU2010232647A1 (en) Peri-fused pyrazolo-pyrimidine compounds
EP2414357A1 (en) Pyrazolo-pyrrolopyridine-dione derivatives useful in the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080064993.9

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2788450

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010339531

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20127020146

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1958/KOLNP/2012

Country of ref document: IN

Ref document number: 2010841700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12012501556

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2010339531

Country of ref document: AU

Date of ref document: 20101229

Kind code of ref document: A